Soler V - Search Results

1

Anti-CD160, Alone or in Combination With Bevacizumab, Is a Potent Inhibitor of Ocular Neovascularization in Rabbit and Monkey Models.

Menguy T, Briaux A, Jeunesse E, Giustiniani J, Calcei A, Guyon T, Mizrahi J, Haegel H, Duong V, Soler V, Brousset P, Bensussan A, Raymond Letron I, Le Bouteiller P. Menguy T, et al. Among authors: soler v. Invest Ophthalmol Vis Sci. 2018 Jun 1;59(7):2687-2698. doi: 10.1167/iovs.18-24024. Invest Ophthalmol Vis Sci. 2018. PMID: 29860455

2

Neuro-ophthalmological changes in healthy females exposed to a 5-day dry immersion: a pilot study.

Kermorgant M, Chedmail T, Varenne F, Bareille MP, Beck A, Billette de Villemeur R, Fournié P, Grondin L, Hélissen O, Membrives C, Nasr N, Pavy-Le Traon A, Soler V. Kermorgant M, et al. Among authors: soler v. NPJ Microgravity. 2024 Jan 11;10(1):4. doi: 10.1038/s41526-024-00344-0. NPJ Microgravity. 2024. PMID: 38212301 Free PMC article.

3

Eye-Rubbing Detection Tool Using Artificial Intelligence on a Smartwatch in the Management of Keratoconus.

Drira I, Louja A, Sliman L, Soler V, Noor M, Jamali A, Fournie P. Drira I, et al. Among authors: soler v. Transl Vis Sci Technol. 2024 Dec 2;13(12):16. doi: 10.1167/tvst.13.12.16. Transl Vis Sci Technol. 2024. PMID: 39666356 Free PMC article.

4

NC1 long and NC3 short splice variants of type XII collagen are overexpressed during corneal scarring.

Massoudi D, Malecaze F, Soler V, Butterworth J, Erraud A, Fournié P, Koch M, Galiacy SD. Massoudi D, et al. Among authors: soler v. Invest Ophthalmol Vis Sci. 2012 Oct 19;53(11):7246-56. doi: 10.1167/iovs.11-8592. Invest Ophthalmol Vis Sci. 2012. PMID: 22969073

5

Iontophoresis Transcorneal Delivery Technique for Transepithelial Corneal Collagen Crosslinking With Riboflavin in a Rabbit Model.

Cassagne M, Laurent C, Rodrigues M, Galinier A, Spoerl E, Galiacy SD, Soler V, Fournié P, Malecaze F. Cassagne M, et al. Among authors: soler v. Invest Ophthalmol Vis Sci. 2016 Feb;57(2):594-603. doi: 10.1167/iovs.13-12595. Invest Ophthalmol Vis Sci. 2016. PMID: 24644053 Free article.

6

Risk Factors for Progressive Myopia in the Atropine Therapy for Myopia Study.

Soler VJ, Malecaze FJ, Salmon L, Cassagne M. Soler VJ, et al. Am J Ophthalmol. 2015 Aug;160(2):395-6. doi: 10.1016/j.ajo.2015.05.006. Am J Ophthalmol. 2015. PMID: 26187883 No abstract available.

7

[Inefficacy of aflibercept in the treatment of idiopathic macular telangiectasia type 2 without neovascularization].

Bénichou J, Soler V, Denis D, Matonti F. Bénichou J, et al. Among authors: soler v. J Fr Ophtalmol. 2017 Sep;40(7):547-551. doi: 10.1016/j.jfo.2016.05.014. Epub 2017 Aug 10. J Fr Ophtalmol. 2017. PMID: 28803666 French.

8

Optic Flow Processing in Patients With Macular Degeneration.

Guénot J, Trotter Y, Fricker P, Cherubini M, Soler V, Cottereau BR. Guénot J, et al. Among authors: soler v. Invest Ophthalmol Vis Sci. 2022 Nov 1;63(12):21. doi: 10.1167/iovs.63.12.21. Invest Ophthalmol Vis Sci. 2022. PMID: 36378131 Free PMC article.

9

[Dynamic phototherapy with silicone oil in treating choroidal subfoveal neovascularization in high myopia].

Soler V, Pagot-Mathis V, Quintyn JC. Soler V, et al. J Fr Ophtalmol. 2011 Oct;34(8):561.e1-4. doi: 10.1016/j.jfo.2011.03.007. Epub 2011 May 12. J Fr Ophtalmol. 2011. PMID: 21570149 French.

10

Five-year follow-up of bilateral choroidal neovascularization secondary to optic nerve head drusen treated with ranibizumab in a nine-year-old girl.

Benouaich X, Salmon L, Mahieu L, Soler V. Benouaich X, et al. Among authors: soler v. J Fr Ophtalmol. 2016 Apr;39(4):e105-8. doi: 10.1016/j.jfo.2015.01.026. Epub 2016 Mar 3. J Fr Ophtalmol. 2016. PMID: 26949117 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

139 results

Search Page

Filters